Amarin Corporation plc AMRN
Amarin Corporation plc (Nasdaq: AMRN) is a cardio-renal-metabolic drug developer. Its lead program, VASCEPA (icosapent ethyl), is marketed for Cardiovascular risk reduction in high-risk statin-treated patients with elevated triglycerides.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VASCEPA (icosapent ethyl) | CV risk reduction (REDUCE-IT indication); severe hypertriglyceridemia (MARINE indication) | small molecule | Approved |
Recent results and decisions
- Oct 25, 2026positive EMT2 investigator-initiated Phase 3 trial showed VASCEPA's potential as add-on therapy for improving outcomes in patients undergoing liver resection for colorectal cancer liver metastases.
The research presented by the Chief Investigator, Professor Mark Hull, added to the scientific understanding of VAZKEPA/VASCEPA, and its potential role as an add-on therapy in improving outcomes for patients undergoing liver resection and standard of care treatment for colorectal cancer liver metast
Filing - Oct 25, 2026positive EMT2 Phase 3 investigator-initiated trial showed potential for VASCEPA as add-on therapy to improve outcomes for patients with colorectal cancer liver metastases.
The research presented by the Chief Investigator, Professor Mark Hull, added to the scientific understanding of VAZKEPA/VASCEPA, and its potential role as an add-on therapy in improving outcomes for patients undergoing liver resection and standard of care treatment for colorectal cancer liver metast
Filing - Oct 25, 2026positive Investigator-initiated Phase 3 trial (EMT2) presented at ESMO 2026 showed potential role for VASCEPA as add-on therapy in improving outcomes for patients with colorectal cancer liver metastases undergoing liver resection.
The research presented by the Chief Investigator, Professor Mark Hull, added to the scientific understanding of VAZKEPA/VASCEPA, and its potential role as an add-on therapy in improving outcomes for patients undergoing liver resection and standard of care treatment for colorectal cancer liver metast
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved cardio-renal-metabolic companies
- AtriCure, Inc. ATRC
- Artivion, Inc. AORT
- Scienture Holdings, Inc. SCNX
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.